Request Demo
Recent blog posts
Latest Hotspot
8 min read
Atopic Dermatitis Indication Strategy Report 2026: IL-4Rα, IL-13, Trials and Deals
17 July 2026
Atopic Dermatitis Indication Strategy Report 2026: IL-4Rα, IL-13, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.
Latest Hotspot
8 min read
Lupus Nephritis Indication Strategy Report 2026: BAFF, CD20, Trials and Deals
17 July 2026
Lupus Nephritis Indication Strategy Report 2026: BAFF, CD20, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.
Latest Hotspot
8 min read
Multiple Myeloma Indication Strategy Report 2026: BCMA, GPRC5D, Trials and Deal Outlook
17 July 2026
A 2026 multiple myeloma strategy report covering disease burden, BCMA and GPRC5D biology, clinical competition, deal activity and portfolio positioning.
Latest Hotspot
8 min read
Alzheimer's Disease Indication Strategy Report 2026: Amyloid-β, Tau, Trials and $2.2B Deal
17 July 2026
Alzheimer's Disease Indication Strategy Report 2026: Amyloid-β, Tau, Trials and $2.2B Deal uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.
Latest Hotspot
8 min read
Non-Small Cell Lung Cancer Indication Strategy Report 2026: EGFR, KRAS, Trials and Deal Outlook
17 July 2026
A 2026 NSCLC indication strategy report covering epidemiology, EGFR and KRAS biology, Phase 3 competition, deal activity and R&D positioning.
Latest Hotspot
8 min read
Inflammatory Bowel Disease Indication Strategy Report 2026: Unmet Need, Competition, Targets and Market Attractiveness
17 July 2026
Inflammatory Bowel Disease 2026 strategy: unmet need, clinical competition, target mechanisms and 2023–2026 deal signals from PatSnap MCP workflows.
Latest Hotspot
8 min read
MASH Indication Strategy Report 2026: Epidemiology, Target Biology, Clinical Competition and Deal Outlook
17 July 2026
A 2026 MASH indication strategy report covering disease burden, THR-β and FGF21 biology, clinical competition, deal activity and R&D positioning.
Latest Hotspot
8 min read
Obesity Indication Strategy Report 2026: Unmet Need, Competition, Targets and Market Attractiveness
17 July 2026
Obesity 2026 strategy: unmet need, clinical competition, target mechanisms and 2023–2026 deal signals from PatSnap MCP workflows.
Latest Hotspot
8 min read
Repare Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
17 July 2026
Repare Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Zentalis Pharmaceuticals Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
17 July 2026
Zentalis Pharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
IDEAYA Biosciences Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
17 July 2026
IDEAYA Biosciences 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
NCT07694986 Trastuzumab HER2-Low Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 July 2026
A focused 2026 clinical landscape deep dive into NCT07694986, evaluating Trastuzumab in HER2-Low Breast Cancer: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.